News

Zenas BioPharma Charts Ambitious Course for Autoimmune Therapies

Zenas BioPharma Charts Ambitious Course for Autoimmune Therapies

Zenas BioPharma Outlines Significant Progress and Goals

- Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x Fc?RIIb inhibitor of B cell function-

- Topline results from Phase 2 Trial in Relapsing Multiple Sclerosis expected in 2025-

- Topline results from pivotal Phase 3 Trial in Immunoglobulin G4-Related Disease expected by year-end 2025-

- Enrollment of Phase 2 Trial in Systemic Lupus Erythematosus expected to be completed in 2025-

- Out-licensed greater-China anti-IGF-1R Thyroid Eye Disease programs.

Zenas BioPharma, Inc. (Nasdaq: ZBIO), a leading clinical-stage biopharmaceutical company, is dedicated to developing therapies for autoimmune diseases. Recently, Zenas highlighted its achievements for 2024 and detailed its strategic objectives for 2025. The company also disclosed its preliminary cash balance, reinforcing its financial stability as it navigates the complexities of drug development.

“We are entering 2025 positioned to capitalize on significant milestones driven by our ongoing obexelimab clinical trials,” said Lonnie Moulder, Founder and CEO. “The dedication of our team has ensured we enter this year with a robust financial foundation and clear objectives.”

As of the end of 2024, Zenas reported a cash reserve of approximately $350 million. This funding is expected to facilitate its ongoing operational expenses and capital projects well into 2026.

Key 2024 Accomplishments

The Company made substantial progress in 2024, achieving multiple important milestones:

  • Completed enrollment in the Phase 3 INDIGO trial of obexelimab for patients with Immunoglobulin G4-Related Disease, representing the largest clinical trial undertaken for this patient demographic.
  • Initiated the MoonStone trial, evaluating the safety and efficacy of obexelimab in patients with Relapsing Multiple Sclerosis.
  • Initiated the SunStone trial focused on patients with Systemic Lupus Erythematosus, assessing the clinical benefits of obexelimab.
  • The Phase 2 SApHiAre trial demonstrated clinical proof-of-mechanism with obexelimab, showcasing its potential for increasing hemoglobin and red blood cell levels.
  • Successfully completed a Series C funding round, raising $458.7 million to expedite development programs.
  • Enhanced leadership with the appointment of Orlando Oliveira as Chief Commercial Officer and Jeff Held as Chief Legal Officer.

Looking Ahead: 2025 Clinical Milestones

In 2025, Zenas aims to hit several crucial clinical benchmarks with obexelimab:

  • Reporting results from the Phase 2 MoonStone trial in the third quarter, focusing on patients with Relapsing Multiple Sclerosis.
  • Progressing through ongoing clinical evaluations of obexelimab, designed to inhibit B cell activity linked to autoimmune diseases.
  • Publishing topline results from the pivotal Phase 3 INDIGO trial regarding the treatment of Immunoglobulin G4-Related Disease.
  • Completion of enrollment in the Phase 2 SunStone trial and subsequent results expected by early 2026.

More broadly, the overall landscape for autoimmune disease treatment is rapidly evolving. There is an increasing understanding of the significant role B cells play in various autoimmune disorders. This essential knowledge positions obexelimab as a unique therapeutic opportunity due to its ability to inhibit rather than deplete B cells, aligning with observed clinical needs.

About Zenas BioPharma, Inc.

As a clinical-stage company, Zenas BioPharma is focused on innovating transformative therapies for autoimmune diseases. The lead product candidate, obexelimab, exemplifies the company’s commitment to addressing unmet medical needs by providing effective, self-administered treatment options via subcutaneous injections. This strategic approach melds a proficient leadership team with targeted acquisition strategies to identify promising drug candidates worldwide.

Frequently Asked Questions

What is obexelimab?

Obexelimab is a bifunctional monoclonal antibody targeting CD19 and Fc?RIIb, aimed at inhibiting B cell function in autoimmune diseases.

What are the main goals for Zenas BioPharma in 2025?

Zenas aims to achieve key clinical milestones, including reporting results from trials for Relapsing Multiple Sclerosis and Immunoglobulin G4-Related Disease.

What financial position is Zenas in as of 2024?

The company reported approximately $350 million in cash, allowing them to cover operational expenses into 2026.

What diseases does Zenas address?

Zenas focuses on autoimmune diseases, including Relapsing Multiple Sclerosis, Systemic Lupus Erythematosus, and Immunoglobulin G4-Related Disease.

How does obexelimab differ from traditional therapies?

Unlike traditional therapies that deplete B cells, obexelimab inhibits their function while preserving their presence, potentially reducing adverse effects and improving treatment outcomes.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 73

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
Pompeii Fountain Tests the Value of Concrete Durability

Updated Category News Views 96

Nearly 2,000 nozzles throwing water around a public attraction is a fine way to expose every weak seam in a concrete job. The Fontana Danzante in Pompei, completed in late 2025, is not some quiet decorative basin. It is described as Italy's largest fountain, a nearly 200-meter installation near the Pompeii Archaeological Park that continuously stores, circulates and...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 51

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
Veterinary Biologics Growth Has a Valuable Catch Ahead

Updated Category News Views 124

Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...

Continue Reading
Atalanta Takes Formal Verification Into Critical Systems

Updated Category News Views 370

A week of bewildering infrastructure failures is a nasty time to discover nobody can explain the machinery. That was the backdrop for Atalanta CEO and co-founder Anjana Rajan at the National Academies of Sciences, Engineering, and Medicine's Cyber Resilience Forum, which concluded November 20 after two days in Washington. Her central point deserves more attention than the...

Continue Reading
Morrison Tests Abu Dhabi as Its Next Capital Hub

Updated Category News Views 97

Abu Dhabi keeps collecting infrastructure managers the way a strong port collects ships: because the money, the policy ambition, and the projects are all converging there. Morrison’s decision to establish an office in ADGM is not some chest-thumping headline about instant deal flow. It is a practical move by a firm with nearly four decades behind it and more than US$35...

Continue Reading
OU's $44.3M Rural Care Plan Targets Oklahoma Care Gaps

Updated Category News Views 70

A Long Drive Is a Brutal Barrier to Care Seventy-five of Oklahoma's 77 counties sit in health professional shortage territory, a figure that ought to stop people cold. It means at least 3,500 patients per provider in those counties. That is not some abstract planning headache. It is the pregnant patient delaying a specialist visit, the family weighing an ambulance ride,...

Continue Reading
Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 60

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 23

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 90

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading

Top 5 Most Recently Viewed Articles

Examining the Latest Trends in Beyond Meat's Short Selling

Updated Category News Views 624

Understanding Beyond Meat's Short Interest Dynamics Beyond Meat (NASDAQ: BYND) has seen an increase in its short percent of float, now at 4.44% higher than the last report. Currently, 24.77 million shares have been sold short, constituting a substantial 39.78% of the total shares available for trading. Given the current trading volume, it would take approximately 10.11...

Continue Reading
Vestis Corporation Faces Class Action Amid Financial Woes

Updated Category News Views 231

Vestis Corporation's Class Action Lawsuit Announcement Pomerantz LLP has formally announced a class action lawsuit targeting Vestis Corporation (NASDAQ: VSTS). This lawsuit stems from allegations of securities fraud and other improper business practices potentially committed by the Company and its executives. Investors who have incurred losses from their investments in...

Continue Reading
Join Ring Energy's Insightful Fireside Chat on Industry Trends

Updated Category News Views 192

Exciting Participation of Ring Energy in Upcoming Fireside Chat Ring Energy, Inc. (NYSE American: REI) has announced its upcoming participation in a noteworthy fireside chat hosted by Water Tower Research. Insights from Industry Leaders This engaging discussion is scheduled to take place at 10:00 AM Central Time, featuring Paul McKinney, the Chairman and Chief Executive...

Continue Reading
SEGG Media's Exciting Leap into NBA Advertising Strategy

Updated Category News Views 191

SEGG Media Strengthens Presence in the NBA SEGG Media Corporation has made significant strides in expanding its brand influence within the U.S. sports landscape. The company, which is the parent organization of Sports.com, has recently announced a strategic initiative to feature full-page advertisements in yearbooks for seven premier NBA teams during the upcoming season....

Continue Reading
Federal Home Loan Bank of Atlanta Reports Q3 2024 Financial Overview

Updated Category News Views 95

Financial Highlights of Federal Home Loan Bank of Atlanta The Federal Home Loan Bank of Atlanta has recently shared its preliminary financial highlights for the third quarter of 2024, showcasing important metrics and performance results. The Bank's quarterly outcomes signal core functionalities and adjustments aimed at sustaining a strong financial foundation. Key...

Continue Reading